Organophosphate And Carbamate Poisoning – Pipeline Review, H2 2013
Organophosphate And Carbamate Poisoning – Pipeline Review, H2 2013
Summary
Global Markets Direct’s, ‘Organophosphate And Carbamate Poisoning – Pipeline Review, H2 2013’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Organophosphate And Carbamate Poisoning, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Organophosphate And Carbamate Poisoning. Organophosphate And Carbamate Poisoning – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– A snapshot of the global therapeutic scenario for Organophosphate And Carbamate Poisoning.
– A review of the Organophosphate And Carbamate Poisoning products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
– Coverage of products based on various stages of development ranging from discovery till registration stages.
– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
– Coverage of the Organophosphate And Carbamate Poisoning pipeline on the basis of route of administration and molecule type.
– Key discontinued pipeline projects.
– Latest news and deals relating to the products.
Reasons to buy
– Identify and understand important and diverse types of therapeutics under development for Organophosphate And Carbamate Poisoning.
– Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
– Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
– Devise corrective measures for pipeline projects by understanding Organophosphate And Carbamate Poisoning pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Organophosphate And Carbamate Poisoning Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Organophosphate And Carbamate Poisoning 7
Organophosphate And Carbamate Poisoning Therapeutics under Development by Companies 9
Organophosphate And Carbamate Poisoning Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Organophosphate And Carbamate Poisoning Therapeutics - Products under Development by Companies 14
Organophosphate And Carbamate Poisoning Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Organophosphate And Carbamate Poisoning Therapeutics Development 16
Baxter International Inc. 16
PharmAthene, Inc. 17
Protalix BioTherapeutics, Inc. 18
MicroDose Therapeutx, Inc. 19
Organophosphate And Carbamate Poisoning - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
PRX-105 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
MDT-011 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
atropine sulfate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Plasma Derived Butyrylcholinesterase - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Organophosphate Antidote CR - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Second Generation Protexia - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Organophosphate And Carbamate Poisoning Therapeutics - Drug Profile Updates 32
Organophosphate And Carbamate Poisoning Therapeutics - Dormant Products 34
Organophosphate And Carbamate Poisoning - Product Development Milestones 35
Featured News & Press Releases 35
Apr 17, 2013: PharmAthene's Recombinant Butyrylcholinesterase Successfully Targets Nerve Agents In In-Vitro Study 35
Jun 07, 2011: MicroDose Therapeutx Announces Successful Completion Of Phase I Pilot Study Of Inhaled Atropine As Antidote To Combat Effects Of Nerve Agent Poisoning 35
Jan 04, 2011: Protalix To Present PRX-105 Data At BARDA Industry Day 36
Jun 08, 2010: Protalix Completes Phase I Clinical Trial For PRX-105 37
Sep 23, 2009: MicroDose Therapeutx Announces Initiation Of Phase I Study With Inhaled Atropine As Antidote To Combat Effects Of Nerve Agent Poisoning 37
May 15, 2007: King Pharmaceuticals AtroPen Receives DHS Safety Act Designation 38
Jun 20, 2003: King Pharmaceuticals Atropen Approved By FDA 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41
List of Tables
Number of Products Under Development for Organophosphate And Carbamate Poisoning, H2 2013 7
Products under Development for Organophosphate And Carbamate Poisoning - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Clinical Stage Development, H2 2013 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
Baxter International Inc., H2 2013 16
PharmAthene, Inc., H2 2013 17
Protalix BioTherapeutics, Inc., H2 2013 18
MicroDose Therapeutx, Inc., H2 2013 19
Assessment by Monotherapy Products, H2 2013 20
Assessment by Stage and Route of Administration, H2 2013 22
Assessment by Stage and Molecule Type, H2 2013 24
Organophosphate And Carbamate Poisoning Therapeutics - Drug Profile Updates 32
Organophosphate And Carbamate Poisoning Therapeutics - Dormant Products 34
List of Figures
Number of Products under Development for Organophosphate And Carbamate Poisoning, H2 2013 7
Products under Development for Organophosphate And Carbamate Poisoning - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Mid Clinical Stage Products, H2 2013 11
Early Clinical Stage Products, H2 2013 12
Discovery and Pre-Clinical Stage Products, H2 2013 13
Assessment by Monotherapy Products, H2 2013 20
Assessment by Route of Administration, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 22
Assessment by Molecule Type, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 24